Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Skye Bioscience, Inc.(SKYE) Shareholders

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Skye Bioscience's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].